Qlife Holding AB (OSTO:QLIFE) Current Deferred Revenue: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:QLIFE Qlife Holding AB OSTO:QLIFE
13 GF Score
Price kr1.94
GF Value kr0.74
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Qlife Holding AB Current Deferred Revenue?

Qlife Holding AB OSTO:QLIFE -0.21% 13 Current Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:QLIFE with a GF Score™ of 13/100 and a GF Value™ of kr0.74 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Qlife Holding AB's current deferred revenue for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Qlife Holding AB Current Deferred Revenue Related Terms

Qlife Holding AB Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Qlife Holding AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qlife Holding AB Current Deferred Revenue Chart

Qlife Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Qlife Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:QLIFE
13GF Score
Qlife Holding AB OSTO:QLIFE
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of kr0.00 Mil mean?
Qlife Holding AB (OSTO:QLIFE) has a Current Deferred Revenue of kr0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Qlife Holding AB and its competitors.
Is Qlife Holding AB's Current Deferred Revenue too high?
Qlife Holding AB's current Current Deferred Revenue is kr0.00 Mil. Overall, Qlife Holding AB has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's Current Deferred Revenue compare to ABT and SYK?
Qlife Holding AB's Current Deferred Revenue of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Qlife Holding AB and its competitors. Qlife Holding AB's current Current Deferred Revenue is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.74, compared to a current price of kr1.94 — trading 161.6% above its estimated fair value. The current Current Deferred Revenue is kr0.00 Mil. Qlife Holding AB's overall GF Score™ is 13/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current Current Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued. The current stock price of kr1.94 is trading 161.6% above its estimated GF Value™ of kr0.74. GuruFocus considers Qlife Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:QLIFE:

  • Current Deferred Revenue: kr0.00 Mil
  • GF Value™: kr0.74 vs. price of kr1.94 (161.6% above fair value)
  • GF Score™: 13/100 with 9 warning signs

No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qlife Holding AB Business Description

Other Exchanges 4HG0:Germany
Address Nellikevagen 22, Goteborg, SWE, SE-412 63
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
13GF Score

Get the complete analysis for OSTO:QLIFE

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.94
Price
kr0.74
GF Value